CRINETICS PHARMACEUTIC

Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024

16 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Oct 2024 15:40:28 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

08 Oct 2024 22:55:11 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

08 Oct 2024 15:01:51 By Nasdaq GlobeNewswire

Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly

26 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Sep 2024 15:40:25 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences

29 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 15:05:01 By Nasdaq GlobeNewswire

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

18 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jul 2024 18:29:44 By Nasdaq GlobeNewswire

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

18 Jun 2024 15:30:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Jun 2024 17:35:30 By Nasdaq GlobeNewswire

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

03 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

03 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

30 May 2024 15:05:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

22 May 2024 07:00:00 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 May 2024 16:38:21 By Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 15:05:00 By Nasdaq GlobeNewswire